Asimadoline - Tioga Pharmaceuticals
Alternative Names: EMD-61753; EMR 63 320; ONO-3951; TP-0052Latest Information Update: 03 Jul 2025
At a glance
- Originator Merck KGaA
- Developer Merck KGaA; Ono Pharmaceutical; Tioga Pharmaceuticals
- Class Acetamides; Opioid analgesics; Pyrrolidines; Small molecules
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pruritus; Vasomotor symptoms
- Discontinued Irritable bowel syndrome; Pain; Postoperative ileus
Most Recent Events
- 01 Jul 2025 Phase-II clinical trials in Vasomotor symptoms (In adults) in USA (PO) (NCT07042516)
- 09 Apr 2021 Asimadoline is still in phase II trials for Pruritus (In adults, In the elderly) in USA (PO) (Tioga Pharmaceuticals pipeline, April 2021)
- 04 Dec 2017 Safety and efficacy data from a phase II clinical trial in Pruritus released by Tioga Pharmaceuticals